Anales de la RANM

34 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LINFOMA DIFUSO DE CÉLULA GRANDE B José María Fernández-Rañada An RANM · Año 2020 · número 137 (01) · páginas 27 a 34 11. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258-2263. 12. Philip T, Guglielmi C, Ilagenbeek A, et al. Au- tologous bone marrow transplantation as com- pared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lympho- ma. N Engl J Med. 1995;333(23):1540-1545. 13. Gisselbrecht C, Glass B, Mounier N, et al. Salva- ge regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituxi- mab era. J Clin Oncol. 2010;28(27):4184-4190. 14. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016;34(26):3150-3156. 15. Dreger P, Sureda A, Ahn KW, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019;3(3):360-369. 16. Herrera AF, Rodig SJ, Song JY, et al. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expres- sor Lymphoma. Biol Blood Marrow Transplant. 2018;24(3):514-520. 17. Polson AG, Yu SF, Elkins K, et al. Antibody- drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616-623. 18. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab ve- dotin in relapsed or refractory B-cell non- Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-715. 19. Cohen JB. Novel therapies for relapsed/refrac- tory aggress1ve lymphomas. Hematology Am Soc Hematol Educ Program. 2018(1):75-82. 20. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clini- cal trial results of available products. Ther Adv Hematol 2019;10:1-20. 21. Locke FL, Ghobadi A, Jacobson CA et al. Long- term safety and activity of axicabtagene ci- loleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:3 l-42. 22. Brudno JN, Kochenderfer JN. Recent advan- ces in CAR T-cell toxicity: Mechanisms, ma- nifestations and management. Blood Rev. 2019;34:45-55. DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en la presente revisión. Si desea citar nuestro artículo: Fernández-Rañada J. M. Linfoma difuso de celula grande B ANALES RANM [Internet]. Real Academia Nacional de Medicina de España; An RANM · Año 2020 · número 137 (01) · páginas 27 – 34 DOI: 10.32440/ar.2020.137.01.rev03